HC Wainwright reconfirms vertex purchase ratings after ADA meeting results

Vertex Pharmaceuticals Incorporated (NASDAQ:vrtx) rank between Best stocks to buy according to hedge funds. With a price target of $550, HC Wainwright reaffirmed its purchase rating for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on June 23rd. The update comes after the American Diabetes Association (ADA) conference featured updates from Vertex’s Zimislecel program.

Clinical findings showed that 10 of the 12 patients, or all 83%, became insulin independent. Furthermore, as evidence of the potential efficacy of the treatment, HC Wainwright reported that all study participants achieved primary composite endpoints with sustained C-peptide recovery.

In particular, as Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) aims to expand the field of treatment, the Zimislecel program represents an element of the company’s pipeline beyond major cystic fibrosis therapy.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a global biotechnology company involved in the discovery and development of small molecule drugs for the treatment of severe diseases, including cystic fibrosis.

While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater potential for a rise and pose a risk of a decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.

read more: 10 Best Magic Formula Stocks of 2025 and Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.